A single-centre prospective study comparing efficacy and safety of apremilast with cyclosporine in moderate to severe atopic dermatitis.

Harshita Ravindra Vyas Shikha R ShahBela J ShahKirti S ParmarNeha JangidAnkita ChoudharyTarun GehlawatDeval Mistry

Published in: The Australasian journal of dermatology (2023)

Apremilast demonstrated lesser efficacy in comparison to cyclosporine; it has the advantage of a favourable safety profile and requires no laboratory monitoring.

Keyphrases

atopic dermatitis
high intensity
early onset